This proposal is a competitive renewal for an investigator-initiated, randomize, double-blind, multicenter, clinical trial currently testing the primary null hypothesis that, up to two years, warfarin and aspirin therapy will not differ in the frequency of death or ischemic stroke recurrence. Secondary null hypotheses are that warfarin and aspirin therapy will not differ in frequency of death or ischemic stroke recurrence over one year; that the effect of warfarin therapy, compared to aspirin, on death or stroke recurrence, will not be modified by baseline stroke severity, baseline stroke subtype, baseline lesion size, location of baseline infarct, ethnicity, gender, and age; and that warfarin and aspirin therapy will not differ in frequency of complications. Aspirin 325 mg daily is the platelet antiaggregant. Warfarin dose is adjusted to keep the INR at 1.4 to 2.8. Patients with ischemic stroke due to cardiac embolism or treated by endarterectomy are ineligible. Patients are randomized within 30 days after stroke and treated for up to two years, followed monthly by phone and quarterly in person to regulate the hematologic effects of medication and to detect the primary endpoints of death and symptomatic stroke recurrence, and to detect complications of therapy. To maintain blinding, the laboratory data are sent to the Data Management Center. PT/INR results sent to the local centers are correct for patients on active warfarin but are falsified for those on aspirin. An emergency notification system helps maintain patient safety. Through 24-Oct-1996 1603 patients have been recruited from 49 participating centers toward the 1,920 patient sample size.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS028371-07
Application #
2735597
Study Section
Special Emphasis Panel (ZNS1-SRB-P (M2))
Program Officer
Marler, John R
Project Start
1992-07-13
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Neurology
Type
Schools of Medicine
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Amory, Colum F; Levine, Steven R; Brey, Robin L et al. (2015) Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. Cerebrovasc Dis 40:293-300
Longstreth Jr, W T; Kronmal, Richard A; Thompson, John L P et al. (2013) Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke 44:714-9
Di Tullio, Marco R; Russo, Cesare; Jin, Zhezhen et al. (2009) Aortic arch plaques and risk of recurrent stroke and death. Circulation 119:2376-82
Levine, Steven R; Brey, Robin L; Tilley, Barbara C et al. (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291:576-84
Homma, Shunichi; Di Tullio, Marco R; Sciacca, Robert R et al. (2004) Effect of aspirin and warfarin therapy in stroke patients with valvular strands. Stroke 35:1436-42
Rodriguez, Carlos J; Homma, Shunichi; Sacco, Ralph L et al. (2003) Race-ethnic differences in patent foramen ovale, atrial septal aneurysm, and right atrial anatomy among ischemic stroke patients. Stroke 34:2097-102
Homma, Shunichi; Sacco, Ralph L; Di Tullio, Marco R et al. (2003) Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol 42:1066-72
Homma, Shunichi; Sacco, Ralph L; Di Tullio, Marco R et al. (2002) Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105:2625-31
Ay, Hakan; Oliveira-Filho, Jamary; Buonanno, Ferdinando S et al. (2002) 'Footprints' of transient ischemic attacks: a diffusion-weighted MRI study. Cerebrovasc Dis 14:177-86
Oliveira-Filho, J; Ay, H; Koroshetz, W J et al. (2001) Localization of clinical syndromes using DWI: two examples of the ""capsular"" warning syndrome. J Neuroimaging 11:44-7

Showing the most recent 10 out of 17 publications